Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

1826results about How to "Conducive to survival" patented technology

Neural regeneration peptides and methods for their use in treatment of brain damage

The invention discloses a family of peptides termed NRP compounds or NRPs that can promote neuronal migration, neurite outgrowth, neuronal proliferation, neural differentiation and / or neuronal survival, and provides compositions and methods for the use of NRPs in the treatment of brain injury and neurodegenerative disease. NRP compounds can induce neurons and neuroblasts to proliferate and migrate into areas of damage caused by acute brain injury or chronic neurodegenerative disease, such as exposure to toxins, stroke, trauma, nervous system infections, demyelinating diseases, dementias, and metabolic disorders. NRP compounds may be administered directly to a subject or to a subject's cells by a variety of means including orally, intraperitoneally, intravascularly, and directly into the nervous system of a patient. NRP compounds can be formulated into pharmaceutically acceptable dose forms for therapeutic use. Methods for detecting neural regeneration, neural proliferation, neural differentiation, neurite outgrowth and neural survival can be used to develop other neurally active agents.
Owner:CURONZ HLDG

Simultaneous inhibition of pd-l1/pd-l2

Methods and compositions for treating an infection or disease that results from (1) failure to elicit rapid T cell mediated responses, (2) induction of T cell exhaustion, T cell anergy or both, or (3) failure to activate monocytes, macrophages, dendritic cells and / or other APCs, for example, as required to kill intracellular pathogens. The method and compositions solve the problem of undesired T cell inhibition by simultaneously inhibiting the PD-1 ligands, PD-L1 and PD-L2. The immune response can be modulated by providing antagonists which bind with different affinity, by varying the dosage of agent which is administered, by intermittent dosing over a regime, and combinations thereof, that provides for dissociation of agent from the molecule to which it is bound prior to being administered again. In some cases it may be particularly desirable to stimulate the immune system, then remove the stimulation.
Owner:AMPLIMMUNE

RNA interference for the treatment of heart failure

InactiveUS8404658B2Reduce expressionDecreasing ventricular arrhythmiasOrganic active ingredientsTissue culturePhospholambanTransfection
The present invention relates to targeted RNAi for the treatment of heart failure by modulating defective cardiac Ca2+ homeostasis via decreasing expression or activity of phospholamban (PLB) using adeno-associated virus (AAV) transfection of cardiomyocytes. Methods for decreasing ventricular arrhythmias, as well as methods for overall improvement of survival from heart failure in subjects are also disclosed. Further, the present invention provides methods which can be used to diagnose susceptibility to treatment by RNAi, and includes pharmaceutical compositions, kits and vectors including an RNAi sequence.
Owner:NANOCOR THERAPEUTICS +1

Ink-jet printing of viable cells

ActiveUS7051654B2Facilitate formation of dropletFacilitate survival of cellAdditive manufacturing apparatusMicrobiological testing/measurementViable cellCellular composition
A method for forming an array of viable cells is provided. In one embodiment, the method comprises ink-jet printing a cellular composition containing cells onto a substrate. Upon printing, at least about 25% of the cells remain viable after incubation for 24 hours at 37° C. in a 5% CO2 / 95% O2 environment.
Owner:CLEMSON UNIV RES FOUND

Method for producing melt-infiltrated ceramic composites using formed supports

A method for producing shaped articles of ceramic composites provides a high degree of dimensional tolerance to these articles. A fiber preform is disposed on a surface of a stable formed support, a surface of which is formed with a plurality of indentations, such as grooves, slots, or channels. Precursors of ceramic matrix materials are provided to the fiber preform to infiltrate from both sides of the fiber preform. The infiltration is conducted under vacuum at a temperature not much greater than a melting point of the precursors. The melt-infiltrated composite article substantially retains its dimension and shape throughout the fabrication process.
Owner:GENERAL ELECTRIC CO

N grouping of traffic and pattern-free internet worm response system and method using N grouping of traffic

Provided are N grouping of traffic and pattern-free Internet worm response system and method. According to the method, traffic factors generated by respective worms are grouped into N groups so that a great quantity of Information may be effectively understood and a worm generated afterward is involved with characteristics of a relevant group. Damages of a network or a system predictable through already classified N traffic characteristics are defined so that corresponding step-by-step measures are taken. Characteristics of the grouped worms are quantitatively analyzed so that a danger degree of a new worm is predicted when the new worm appears afterward and forecasting and alarming through the prediction are performed. Easiness with which a controlling operator instantly understands an accident using a visualization method having an approximate real-time characteristic is increased, so that detection efficiency for most worms not detected using a conventional rule is increased.
Owner:ELECTRONICS & TELECOMM RES INST

Application of electrical stimulation for functional tissue engineering in vitro and in vivo

The present invention provides new methods for the in vitro preparation of bioartificial tissue equivalents and their enhanced integration after implantation in vivo. These methods include submitting a tissue construct to a biomimetic electrical stimulation during cultivation in vitro to improve its structural and functional properties, and / or in vivo, after implantation of the construct, to enhance its integration with host tissue and increase cell survival and functionality. The inventive methods are particularly useful for the production of bioartificial equivalents and / or the repair and replacement of native tissues that contain electrically excitable cells and are subject to electrical stimulation in vivo, such as, for example, cardiac muscle tissue, striated skeletal muscle tissue, smooth muscle tissue, bone, vasculature, and nerve tissue.
Owner:MASSACHUSETTS INST OF TECH

Cancer stem cell expression patterns and compounds to target cancer stem cells

Described herein are therapeutic targets expressed in cancer stem cells and methods for treating and diagnosing cancer by targeting such cells with antibodies, compounds, nucleic acid, or other therapeutic agent. In one embodiment described herein, therapeutic agents for the treatment of cancer are provided based on the identification of cancer stem cell targets. The present invention also includes therapeutic targets for cancer therapy and cancer stem cell-targeted therapy. The invention includes the treatment of cancer by the administration of compounds or agents that target cancer stem cells.
Owner:THE JOHNS HOPKINA UNIV

Methods and Compositions for Mammalian Cell Lines for Transfection and Protein Expression in Serum-Free Medium

Disclosed are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hormones, and vaccines. Cells transfected with an apoptosis-inhibiting gene or vector, such as a triple mutant Bcl-2 gene, can survive longer in culture, resulting in extension of the state and yield of protein biosynthesis. Such transfected cells exhibit maximal cell densities that equal or exceed the maximal density achieved by the parent cell lines. Transfected cells can also be pre-adapted for growth in serum-free medium, greatly decreasing the time required to obtain protein production in serum-free medium. In certain methods, the pre-adapted cells can be used for protein production following transfection under serum-free conditions. In preferred embodiments, the cells of use are SpESF or SpESF-X cells.
Owner:IMMUNOMEDICS INC

Methods for treating muscle diseases and disorders

The invention relates to methods of treating diseases and disorders of the muscle tissues in a vertebrate by the administration of compounds which bind the p185erbB2 receptor. These compounds are found to cause increased differentiation and survival of cardiac, skeletal and smooth muscle.
Owner:ACORDA THERAPEUTICS INC

Methods and means for efficient skipping of at least one of the following exons of the human duchenne muscular dystrophy gene: 43, 46, 50-53

The invention relates a method wherein a molecule is used for inducing and / or promoting skipping of at least one of exon 43, exon 46, exons 50-53 of the DMD pre-mRNA in a patient, preferably in an isolated cell of a patient, the method comprising providing said cell and / or said patient with a molecule. The invention also relates to said molecule as such.
Owner:ACADEMISCH ZIEKENHUIS BIJ DE UNIV VAN AMSTERDAM ACADEMISCH MEDISCH CENT +2

Method and system for modulating energy expenditure and neurotrophic factors

A method system for modulating the energy expenditure and / or the expressed brain-derived neurotrophic factor (BDNF) in the brain of an individual is performed by a system that includes a control device that generates a stimulation pattern from a predetermined set of stimulation parameters, and that converts the stimulation pattern into a stimulation signal. A stimulation signal delivery mechanism, configured for implantation into a selected part of the brain, receives the stimulation signal from the control device and delivers the signal to the selected part of the brain. The stimulation signal may be an electrical signal delivered by a brain-implantable electrode, or a chemical signal in the form of a drug dosage regimen delivered by an implantable micropump under the control of the control device. Modulation of the energy expenditure and / or BDNF is achieved by the stimulation of the hypothalamus, either directly or indirectly, by the stimulation signal.
Owner:RGT UNIV OF CALIFORNIA

Closed System and Method for Atraumatic, Low Pressure, Continuous Harvesting, Processing, and Grafting of Lipoaspirate

A closed system for harvesting fat through liposuction, concentrating the aspirate so obtained, and then re-injecting the concentrated fat into a patient comprises as its main components a low pressure cannula having between about 7 to 12 side holes of about 1-2 mm by 2.0 to 4.0 mm, a spring loaded syringe holder with a helicoidal spring to apply a substantially constant pressure over the full excursion of the plunger, and a preferably flexible collection bag which is also preferably graduated, cylindrical over most of its body and funnel shaped at its bottom, all of which are connected through flexible tubings to a multi-port valve. The multi-port valve has two flutter / duck bill valves which restrict the fluid flow to a one way direction which effectively allows the syringe to be used to pump fat out of a patient and into a collection bag in a continuous manner. After the bags are centrifuged to concentrate the fat, the excess fluids are separated and the valve is re-connected to permit the syringe pump to reverse fluid flow to graft the concentrated fat back into the patient.
Owner:LIPOCOSM LLC

Nicotinoyl riboside compositions and methods of use

ActiveUS20070117765A1Improving cell survivalImproving tissue survivalBiocideSugar derivativesNicotinamide ribosideRiboside
The invention relates to compositions of nicotinoyl ribosides and nicotinamide riboside derivatives and their methods of use. In some embodiments, the invention relates to methods of making nicotinoyl ribosides. In some embodiments, the invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinoyl riboside. In further embodiments, the invention relates to methods of using nicotinoyl ribosides and nicotinamide riboside derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for improving cell and tissue survival.
Owner:CORNELL RES FOUNDATION INC

Methods and compositions based on diphtheria toxin-interleukin-3 conjugates

ActiveUS20080138313A1Enhance or improve the prophylactic effect(s) of another therapyShorten the durationBiocidePeptide/protein ingredientsCancer cellWhite blood cell
The present invention provides methods for inhibiting interleukin-3 receptor-expressing cells, and, in particular, inhibiting the growth of such cells by using a diphtheria toxin-human interleukin-3 conjugate (DT-IL3) that is toxic to cells expressing the interleukin-3 receptor. In preferred embodiments, the DT-IL3 conjugate is a fusion protein comprising amino acids 1-388 of diphtheria toxin fused via a peptide linker to full-length, human interleukin-3. In certain embodiments, the methods of the present invention relate to the administration of a DT-IL3 conjugate to inhibit the growth of cancer cells and / or cancer stem cells in humans, which cells express one or more subunits of the interleukin-3 receptor. Exemplary cells include myeloid leukemia cancer stem cells. In other embodiments, the methods of the present invention relate to ex vivo purging of bone marrow or peripheral blood to remove cells that express one or more subunits of the interleukin-3 receptor such that the purged bone marrow or peripheral blood is suitable, e.g., for autologous stem cell transplantation to restore hematopoietic function.
Owner:SCOTT & WHITE MEMORIAL HOSPITAL

Human Antibodies to Ebola Virus Glycoprotein

The present invention provides monoclonal antibodies, or antigen-binding fragments thereof, that bind to Ebola virus glycoproteins, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for inhibiting or neutralizing Ebola virus activity, thus providing a means of treating or preventing Ebola virus infection in humans. In some embodiments, the invention provides for use of one or more antibodies that bind to the Ebola virus for preventing viral attachment and / or entry into host cells. The antibodies of the invention may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.
Owner:REGENERON PHARM INC

Tm-enhanced blocking oligonucleotides and baits for improved target enrichment and reduced off-target selection

The invention is directed to modified oligonucleotide compositions and methods for selectively reducing unwanted nucleic acid contaminants and enriching for desired nucleic acid targets from complex genomic nucleic acid mixtures for sequencing applications. The modified oligonucleotide compositions include one or more modified groups that increase the Tm of the resultant oligonucleotide composition.
Owner:FOUND MEDICINE INC +1

Antibodies that bind human cd27 and uses thereof

Isolated monoclonal antibodies which bind to human CD27 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
Owner:CELLDEX THERAPEUTICS INC

Antibodies that bind human cd27 and uses thereof

Isolated monoclonal antibodies which bind to human CD27 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
Owner:CELLDEX THERAPEUTICS INC

Methods of culturing embryonic stem cells and controlled differentiation

The present invention provides a preparation of undifferentiated embryonic stem (ES) cells sustainable for a prolonged period in an undifferentiated state which will undergo stem cell renewal or somatic differentiation. Preferably the cells are capable of somatic differentiation in vitro and are inclined to differentiate away from an extraembryonic lineage. The present invention also provides method of culturing embryonic stem (ES) cells to improve stem cell maintenance and persistence in culture. The method also provides a culture of ES cells prepared by the method as well as differentiated cells derived from the embryonic cells resulting from directed differentiation procedures provided by the present invention.
Owner:SINGAPORE NAT UNIV OF +1

Antibodies that bind human CD27 and uses thereof

Isolated monoclonal antibodies which bind to human CD27 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
Owner:CELLDEX THERAPEUTICS INC

Gas systems and methods for enabling respiratory stability

Minimal concentrations of CO2 are mixed with pressurized air to provide a gas mix effective for stabilizing breathing of target patients or users. CO2 concentrations below about 2% and preferably between about 0.5% and 1.25% are employed. A gas modulator includes a gas mixing module, a sensor and a control processor. The gas mixing module mixes plural gases, including CO2, into a gas mix, for delivery to a substantially leak-proof patient face mask. The sensor, located substantially at the face mask, measures CO2 concentration in the face mask. The control processor, based on a signal from the sensor, controls the CO2 concentration in the gas mix.
Owner:BETH ISRAEL DEACONESS MEDICAL CENT INC

Monitoring cancer stem cells

The present invention is directed to methods of monitoring cancer stem cells in patients undergoing cancer therapy to determine whether the cancer therapy is an effective cancer therapy. The present invention relates to methods for monitoring the amount of cancer stem cells prior to, during, and / or following cancer treatment of a patient. In particular, the methods provide measuring the amount of cancer stem cells i) in a sample obtained from a patient and / or ii) in a patient via in vivo imaging, e.g. at different time points before, during or after a treatment regimen for cancer. The change in amount of cancer stem cells over time allows the physician to judge the effectiveness of the treatment regimen and then to decide to continue, alter, or halt the treatment regimen if need be. The present invention also provides kits for monitoring cancer stem cells prior to, during, and / or following cancer treatment of a patient. The present invention also provides for a method of treatment of cancer, wherein such method involves the use of a therapeutic agent that stabilizes or reduces the amount of cancer stem cells in or from a patient.
Owner:STEMLINE THERAPEUTICS

METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA

ActiveUS20120022134A1Reduced calcium uptake by muscle cellsReduce synthesisOrganic active ingredientsSplicing alterationNucleotidePrecursor mRNA
The invention relates to a method for inducing or promoting skipping of exon 45 of DMD pre-mRNA in a Duchenne Muscular Dystrophy patient, preferably in an isolated (muscle) cell, the method comprising providing said cell with a molecule that binds to a continuous stretch of at least 21 nucleotides within said exon. The invention further relates to such molecule used in said method.
Owner:BIOMARIN TECH BV +2
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products